<DOC>
	<DOCNO>NCT00517010</DOCNO>
	<brief_summary>Because possible synergism radiation inhibitor vascular endothelial growth factor show cancer patient patient wet macular degeneration , pilot study conduct determine whether treat wet macular degeneration combination Lucentis proton beam irradiation safe . Lucentis inhibitor vascular endothelial growth factor recently FDA approve treatment wet macular degeneration . It appear effective therapy thus far wet macular degeneration among drug FDA approve condition . If major safety issue associate combination therapy , large study conduct determine whether combination therapy effective Lucentis monotherapy .</brief_summary>
	<brief_title>Pilot Study Lucentis Combined With Proton Beam Irradiation Treating Wet Age-related Macular Degeneration</brief_title>
	<detailed_description>Five subject diagnose wet macular degeneration treat standard care , i.e . intravitreal Lucentis injection monthly first four month need thereafter . Within six week first Lucentis injection , eye also treat 24 Gy proton beam divide two fraction . Each subject follow 2 yr monthly examination .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 50 year Patient relate consideration Able maintain followup least 24 month . Women must postmenopausal without period least one year . Hgb A1C &lt; 6 Diagnosed Agerelated Macular Degeneration ( ARMD ) active subfoveal choroidal neovascular membrane ( CNVM ) , new recurrent Visual acuity 20/60 20/400 Lesion size &lt; 12 Disc Area Submacular hemorrhage le 75 % total lesion Submacular fibrosis le 25 % total lesion Candidate intravitreal Lucentis Prior enrollment study Pregnancy ( positive pregnancy test ) lactation Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous medical investigation trial CNVM within 1 mm disc margin Photodynamic Therapy ( PDT ) within 3 month AntiVEGF therapy within 6 week Intravitreal subtenon 's Kenalog within 6 month Intraocular surgery within 3 month expect next 6 month Current plan participation experimental treatment wet AMD Other concurrent retinopathy optic neuropathy Other cause CNVM , i.e . myopic degeneration ocular histoplasmosis ( POHS ) Significant medium opacity preclude adequate view fundus exam , photography OCT History radiation therapy head study eye Systemic anticoagulation coumadin Head tremor h/o claustrophobia preclude position proton irradiation Inability maintain steady fixation either eye Diabetes mellitus require treatment History Malignancy treat within 5 year Allergy Fluorescein dye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Age-related macular degeneration</keyword>
	<keyword>Exudative age-related macular degeneration</keyword>
	<keyword>Wet macular degeneration</keyword>
	<keyword>Intravitreal injection</keyword>
	<keyword>Proton beam irradiation</keyword>
	<keyword>Lucentis</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>